Developing TCR-T cell Therapy for Patients with HIV and HPV-Associated Cancer: Extending a Promising Therapy to Underrepresented Groups
Time: 2:00 pm
day: DAY TWO TRACK 2 B
- Adoptive T cell therapy shows promise but often excludes HIV-positive individuals from cancer trials.
- Evidence suggests full-dose chemotherapy and immunotherapy are safe for HIV-positive cancer patients.
- Retrospective studies indicate comparable safety and efficacy of CD19 CAR T cell therapy in people with HIV and B-cell malignancies.
- We aim to test the safety and efficacy of E7 TCR-T cell therapy in HIV-positive individuals with HPV-associated cancer, an underrepresented group in the US.